Alginate-based sustained release drug delivery systems for tuberculosis

Expert Opinion on Drug Delivery

Volumn 5, Issue 12, 2008, Pages 1323-1334

  Ahmad, Zahoor ^b   Khuller, G K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alginate; Alginate microspheres; Alginate nanoparticles; Antitubercular drugs; Chitosan; Drug delivery system; Liposomes; Microparticles; Poly (dl lactide co glycolide); Solid lipid nanoparticles; Tuberculosis

Indexed keywords

ALGINIC ACID; ANTIBIOTIC AGENT; BCG VACCINE; CHITOSAN; COPOLYMER; CYTARABINE; DENILEUKIN DIFTITOX; DOXORUBICIN; DRUG CARRIER; ETHAMBUTOL; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; ISONIAZID; LIPOSOME; MICROSPHERE; NANOPARTICLE; PEG INTRO; PEGINTERFERON ALPHA2B; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLYSINE; POLYMER; PYRAZINAMIDE; PYRROLE DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STREPTOMYCIN; TOSITUMOMAB I 131; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BIOCOMPATIBILITY; BIODEGRADABILITY; BREAST CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CHEMICAL STRUCTURE; CUTANEOUS T CELL LYMPHOMA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TRANSPORT; DRUG TREATMENT FAILURE; ENCAPSULATION; FEBRILE NEUTROPENIA; HEPATITIS C; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT COMPLIANCE; PHYSICAL CHEMISTRY; REVIEW; SHORT COURSE THERAPY; STRUCTURE ANALYSIS; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TUBERCULOSIS;

ALGINATES; ANTITUBERCULAR AGENTS; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HUMANS; MICROSPHERES; NANOPARTICLES; TUBERCULOSIS;

EID: 58149194837     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240802600662     Document Type: Review

References (57)

1. Dye C, Watt CJ, Bleed DM, et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-75
2. Williams BG, Granich R, Chauhan LS, et al. The impact of HIV/AIDS on the control of tuberculosis in Indi. Proc Natl Acad Sci USA 2005;102:9619-24
3. Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
4. Chaisson RE, Martinson NA. 'Tuberculosis in Africa - combating an HIV-driven crisis' N Engl J Med 2008;358:1089-92
5. Xing Z. The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines. Curr Pharm Des 2001;7:1015-37
6. Kirby DJ, Rosenkrands I, Agger EM, et al. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008;16:282-93
7. Zhu BD, Qie YQ, Wang JL, et al. Chitosan microspheres enhance the immunogenicity of an A985B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm 2007;66:318-26
8. Dobakbti F, Rahimi F, Dehpour AR, et al. Stabilizing effects of calcium alginate microspheres on Mycobac-terium bovis BCG intended for oral vaccination. J Microencapsul 2006;23:844-54
9. Ajdary S, Dobakhti F, Taghikhani M, et al. Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine 2007;25:4595-601
10. Kirby DJ, Rosenkrands I, Agger EM, et al. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J Drug Target 2008;16:543-54
11. du Toit LC, Pillay V, Danck-werts MP. Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 2006;7:118
12. Jain KK. Delivery systems - an overview. Methods Mol Biol 2008;437:1-50
13. Amar HO, Khalil RM. Preparation and evaluation of sustained release solid dispersions of drugs with Eudragit polymers. Drug Dev Ind Pharm 1997;23:1043-54
14. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21(5):387-422
15. Pandey R, Khuller GK. Polymer based drug delivery systems for mycobacterial infections. Curr Drug Del 2004;1:195-201
16. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-55
17. Schatz A, Bugie B, Waksman S. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 1944;55:65-9
18. World Health Organization. Global tuberculosis control: surveillance, planning financing. WHO/HTM/TB/2005. WHO Report 2005; Geneva, Switzerland
19. Chopra P, Meena LS, Singh Y. New drug targets for Mycobacterium. tuberculosis. J Med Res 2003;117:1-9
20. Christine MJ, Pandey R, Sharma S, et al. Oral therapy using nanoparticle encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium. Tuberculosis. Antimicrob Agents Chemother 2005;49:4335-8
21. Giovanni DP, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54:593-602
22. Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005;45:529-64
23. Falk R, Randolph TW, Meyer JD, et al. Controlled release of ionic compounds from poly(L-lactide) microspheres produced by precipitation with a compressed antisolvent. J Contr Rel 1997:441:77-85
24. You JO, Park SB, Park HY, et al. Preparation of regular sized Ca-alginate microspheres using membrane emulsification method. J Microencapsul 2001;18:521-32
25. Smidsrod O, Draget KI. Chemistry and physical properties of alginates. Carbohydr Eur 1996;14:6-13
26. Skjak-Braek G, Espevik T. Application of alginate gels in biotechnology and biomedicine. Carbohydr Eur 1996;14:19-25
27. Takka S, Acarturk F. Calcium alginate microparticles for oral administration: I. effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsul 1999;16:275-90
28. Rajaonarivony M, Vauthier C, Couarraze G, et al. Development of a new drug carrier made from alginate. J Pharm Sci 1993;82:912-17
29. Ostberg T, Vesterhus L, Graffner C. Calcium alginate matrices for oral multiple unit administration: II. Effect of process and formulation factors on matrix properties. Int J Pharm 1993;97:183-93
30. Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm 2002;28:621-30
31. Wong TY, Preston LA, Schiller NL. Alginate lyase: review of major sources and enzyme characteristics, structure-function analysis, biological roles, and applications. Annu Rev Microbiol 2000;54:289-340
32. Matricardi P, Meo CD, Covietto T, Alhaique F. Recent advances and perspectives on coated alginate microspheres for modified drug delivery. Expert Opin Drug Deliv 2008;5(4):417-25
33. Raj NK, Sharma CP. Oral insulin - a perspective. J Biomater Appl 2003;17:183-96
34. Joseph I, Venkataram S. Indomethacin sustained release from alginate-gelatin or pectin-gelatin coacervates. Int J Pharm 1995;126:161-8
35. Gonzalez-Rodriguez ML, Holgado MA, et al. Alginate-chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002;232:225-34
36. Chickering III DE, Jacob JS, Desai TA, et al. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug loaded alginate and poly (fumaric-co-sebacic anhydride) microspheres. J Control Release 1997;48:35-46
37. Iannuccelli V, Coppi G, Cameroni R. Biodegradable intraoperative system for bone infection treatment. I. The drug/polymer interaction. Int J Pharm 1996;143:195-201
38. Cui JH, Gob JS, Park SY, et al. Preparation and physical characterization of alginate microparticles using air atomization method. Drug Dev Ind Pharm 2001;27:309-19
39. Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm 2000;210:45-49
40. Lucinda-Silva RM, Evangelista RC. Microspheres of alginate-chitosan containing isoniazid. J Microencapsul 2003;20:145-52
41. Ain Q, Sharma S, Khuller GK, et al. Alginate based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother 2003;51:931-8
42. Ciofani G, Raffa V, Menciassi A, et al. A drug delivery system based on alginate microspheres: mass-transport test and in vitro validation. Biomed Microdevices 2007;9(3):395-403
43. Samad A, Sultana Y, Khar RK, et al. Radiolabeling and evaluation of alginate blend-isoniazid microspheres by Tc-99m for the treatment of tuberculosis in rabbit model. J Drug Target 2008;16:509-15
44. Takka S, Ocak OH, Acarturk F. Formulation and investigation of nicardiine HC1-alginate gel beads with factorial design-based studies. Eur J Pharm Sci 1998;6:241-6
45. Pandey R, Khuller GK. Chemotherapeutic potential of alginate chitosan microspheres as antitubercular drug carriers. J Anitimicrob Chemother 2004;53:635-40
46. Berrada M, Serreqi A, Dabbarh F, et al. A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 2005;26:2115-20
47. Ahmad Z, Pandey R, Sharma S, et al. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents 2006;27:420-27
48. Ahmad Z, Pandey R, Sharma S, et al. Alginate nanoparticles as antitubercular drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci 2006;48:171-6
49. Ahmad Z, Pandey R, Sharma S, et al. Evaluation of antitubercular drug loaded alginate nanoparticles against experimental tuberculosis. Nanoscience 2005;1:81-5
50. Ahmad Z, Sharma S, Khuller GK. Inhalable Alginate Nanoparticles as Antitubercular Drug Carriers against Experimental Tuberculosis. Int J Antimicrob Agents 2005;26:298-303
51. Guardiola-Diaz HM, Foster LA, Mushrush D, et al. Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium. tuberculosis. Biochem Pharmacol 2001;61:1463-70
52. V. FEMS Microbiol Lett 2005;251:19-22
53. Ahmad Z, Sharma S, Khuller GK. Azole antifungals as novel chemotherapeutic agents against routine tuberculosis. FEMS Microbiol Lett 2006;261:181-86
54. Ahmad Z, Sharma S, Khuller GK. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 2006;258:200-3
55. Ahmad Z, Sharma S, Khuller GK, et al. In vitro antimycobacterial potential of Econazole against multidrug resistant strains of Mycobacterium. tuberculosis. Int J Antimicrob Agents 2006;28(6):543-4
56. Pandey R, Ahmad Z, Sharma S, et al. Nano-encapsulation of azole antifungals: potential applications to improve oral drug bioavailability. Int J Pharm, 2005;301:268-76
57. Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against routine tuberculosis. Nanomedicine 2007;3:239-43.